查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1634211

全球性传染病 (STD) 诊断市场 - 2025 - 2033

Global Sexually Transmitted Diseases (STD) Diagnostics Market - 2025 - 2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年，全球性传染病 (STD) 诊断市场规模达到 106 亿美元，预计到 2033 年将达到 194 亿美元，2025-2033 年预测期间复合年增长率为 7.1%。

性传染病 (STD) 诊断是指用于检测、识别和确认个人是否存在性传染感染 (STI) 的医疗流程和技术。这些疾病主要透过性接触传播，可能由细菌、病毒或寄生虫引起。性病诊断涵盖广泛的实验室检查、临床评估和筛检方法，以在早期阶段（甚至在症状出现之前）检测感染，以便及时治疗并降低传播给他人的风险。

对性传染病 (STD) 诊断的需求是由多种因素推动的，从性健康意识的提高到诊断技术的进步。例如，根据世界卫生组织估计，2020 年，四种性传染病之一的滴虫病（1.56 亿）、淋病（8,200 万）、梅毒（710 万）和衣原体（1.29 亿）的新病例在2020 年发生了3.74 亿例。这些不断增加的性病增加了对性病诊断的需求。

市场动态：

驱动程式和限制

性病自我诊断不断进步

STD 自我诊断的不断进步极大地推动了性传染病 (STD) 诊断市场的成长，预计将在预测期内推动该市场的发展。性传染病自我检测套件允许个人在家中进行检测，无需医疗保健专业人员，使过程更加方便和私密。这一趋势对于减少与性病检测相关的耻辱尤其重要。

例如，新斯科细亚省爱滋病联盟负责人表示，新斯科细亚省将于 2024 年 8 月提供免费的性传染感染家庭检测，这是减少重要性保健障碍的重要一步。

此外，2023 年6 月，LifeCell International 推出了检测试剂盒，让患者在家中私密地收集细胞拭子和组织样本，然后用于检测人类乳突病毒(HPV)，这种病毒会导致女性子宫颈癌和性传染感染，例如梅毒或淋病。

现代自诊断测试旨在提供快速结果，这是市场的重要驱动力。用户可以在 20 分钟到 1 小时内获得测试结果，这对于寻求即时答案的人来说更具吸引力。例如，OraQuick 提供快速 HIV 检测，无需实验室设备即可在 20 分钟内得出结果。这些测试的速度和简便性使其越来越受欢迎，因为个人更有可能使用提供快速回馈的测试。

认识和教育有限

认识和教育有限是性传染病 (STD) 诊断市场成长的重大障碍。儘管诊断技术不断进步，检测选择范围不断扩大，但对性病检测重要性的认识不足以及性健康教育的缺乏阻碍了诊断服务的广泛采用。

许多人不知道与性病相关的风险，尤其是可能被忽视的无症状感染。这种意识的缺乏导致检测率低，特别是对于那些可能不认为自己处于危险之中的人群。例如，根据疾病预防控制中心的数据，美国近五分之一的人患有性病，但许多人由于不寻求检测而仍未被诊断出来。这种情况在披衣菌和淋病等感染中尤其常见，这些感染通常没有任何症状。

许多人因为害怕受到侮辱而避免性病检测，即使他们知道检测的必要性。在保守社会中尤其如此，讨论性健康是禁忌。例如，在印度，文化规范不鼓励公开谈论性健康，这导致检测率较低。 《印度公共卫生杂誌》的一项研究显示，超过 50% 的受访年轻人由于担心社会耻辱而不愿寻求医疗建议或性传染病检测。

目录

第一章：市场介绍和范围

  • 报告的目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分類的片段
  • 依疾病类型分类的片段
  • 按诊断测试类型分類的片段
  • 最终使用者的片段
  • 按地区分類的片段

第 3 章：动力学

  • 影响因素
    • 司机
      • 性病自我诊断的不断进步
    • 限制
      • 意识和教育有限
    • 机会
    • 影响分析

第 4 章：策略洞察与产业展望

  • 市场领导者和先驱
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的知名领导者
    • 拥有成熟产品的市场领导者
  • 新兴新创企业和关键创新者
  • CXO 观点
  • 最新进展和突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：性传染病 (STD) 诊断市场（按产品类型）

  • 仪器仪表
  • 耗材
  • 软体

第 6 章：性传染病 (STD) 诊断市场（按疾病类型）

  • 衣原体
  • 生殖器疱疹
  • 淋病
  • B型肝炎
  • 爱滋病毒/爱滋病
  • 人类乳突病毒 (HPV)
  • 梅毒
  • 其他的

第 7 章：性传染病 (STD) 诊断市场（按诊断测试类型）

  • 分子测试
  • 血清学测试
  • 即时护理 (PoC) 测试
  • 其他的

第 8 章：性传染病 (STD) 诊断市场（按最终用户）

  • 医院
  • 专科诊所
  • 诊断实验室
  • 家庭护理设置
  • 其他的

第 9 章：性传染病 (STD) 诊断市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的主要发展
  • 公司基准化分析

第 11 章：公司简介

  • Abbott Laboratories
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT分析
  • Becton, Dickinson, and Company
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Hologic, Inc.
  • QIAGEN NV
  • Diasorin SpA
  • Seegene Inc.
  • Bosch Healthcare Solutions GmbH

第 12 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 13 章：附录

简介目录
Product Code: CD1785

The global Sexually Transmitted Diseases (STD) diagnostics market reached US$ 10.6 billion in 2024 and is expected to reach US$ 19.4 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033.

Sexually Transmitted Diseases (STD) diagnostics refers to the medical processes and technologies used to detect, identify and confirm the presence of sexually transmitted infections (STIs) in individuals. These diseases are primarily transmitted through sexual contact and can be caused by bacteria, viruses, or parasites. STD diagnostics encompasses a wide range of laboratory tests, clinical evaluations and screening methods to detect infections in their early stages, even before symptoms appear, allowing for timely treatment and reducing the risk of transmission to others.

The demand for sexually transmitted diseases (STD) diagnostics is driven by a variety of factors, ranging from increasing awareness of sexual health to advancements in diagnostic technology. For instance, according to WHO estimates, 374 million new cases of one of the four STIs trichomoniasis (156 million), gonorrhea (82 million), syphilis (7.1 million), and chlamydia (129 million) occurred in 2020. An estimated 300 million women are infected with HPV, the main cause of anal and cervical cancer in males who have sex with men. These rising STDs increase the demand for STD diagnostics.

Market Dynamics: Drivers & Restraints

Rising advancements in STD self-diagnostics

The rising advancements in STD self-diagnostics are significantly driving the growth of the sexually transmitted diseases (STD) diagnostics market and are expected to drive the market over the forecast period. Self-testing kits for STDs allow individuals to test at home without the need for a healthcare professional, making the process more convenient and private. This trend has been particularly important in reducing the stigma associated with STD testing.

For instance, in August 2024, Nova Scotia is going to offer free at-home tests for sexually transmitted infections is an important step toward reducing some barriers to vital sexual health care, says the head of the provincial AIDS coalition.

Additionally, in June 2023, LifeCell International launched test kits that allow patients to collect cell swabs and tissue samples in the privacy of their homes that can then be used for detecting Human Papillomavirus (HPV) which causes cervical cancer in women and sexually transmitted infections like syphilis or gonorrhea.

Modern self-diagnostic tests are designed to provide rapid results, which is a significant driver in the market. Users can get test results in 20 minutes to 1 hour, making it more attractive for those seeking immediate answers. For instance, OraQuick offers a rapid HIV test that delivers results in 20 minutes with no need for laboratory equipment. The speed and ease of these tests contribute to their growing popularity, as individuals are more likely to use tests that provide quick feedback.

Limited awareness and education

Limited awareness and education are significant barriers to the growth of the sexually transmitted diseases (STD) diagnostics market. Despite advances in diagnostic technologies and an increasing range of testing options, insufficient understanding of the importance of STD testing and a lack of education about sexual health have hindered the widespread adoption of diagnostic services.

Many individuals are unaware of the risks associated with STDs, especially asymptomatic infections that can go unnoticed. This lack of awareness leads to low testing rates, especially in populations who might not perceive themselves as being at risk. For instance, according to the CDC, nearly 1 in 5 people in the U.S. are living with an STD, but many remain undiagnosed because they do not seek testing. This is particularly common with infections like chlamydia and gonorrhea, which often present with no symptoms.

Many individuals avoid STD testing due to fear of being stigmatized, even if they are aware of the need for testing. This is particularly true in conservative societies where discussions about sexual health are taboo. For instance, in India, cultural norms discourage open conversations about sexual health, which results in lower testing rates. According to a study by the Indian Journal of Public Health, over 50% of young people surveyed were unwilling to seek medical advice or testing for STDs due to fear of social stigma.

Segment Analysis

The global sexually transmitted diseases (STD) diagnostics market is segmented based on product type, disease type, diagnostic test type, end-user and region.

Disease Type:

The chlamydia segment is expected to dominate the sexually transmitted diseases (STD) diagnostics market share

Chlamydia is one of the most common STDs globally, particularly affecting young adults and adolescents. The Centers for Disease Control and Prevention (CDC) estimates that over 1.8 million new cases of chlamydia are reported annually in the United States alone, making it the most frequently reported STD in the country.

Chlamydia is often asymptomatic, particularly in women, leading to high rates of undiagnosed cases. This makes regular testing crucial, especially among sexually active individuals who may not be aware they are infected. As a result, the demand for routine screening and diagnostic tests increases. Thus, many market players are advancing STD diagnostics for chlamydia testing.

For instance, in May 2024, Sherlock Bio started testing its over-the-counter fast test for identifying STIs including chlamydia, with its plans to sell it by the middle of 2025. In order to compare the accuracy of their CRISPR-based test to widely used lab tests for chlamydia, the business intends to enlist 2,500 sexually active volunteers at 20 research locations around the United States.

Because Chlamydia is highly treatable with antibiotics, early detection and treatment are key to preventing long-term health complications. Many health authorities, including the CDC and the U.S. Preventive Services Task Force (USPSTF), recommend routine screening for Chlamydia for sexually active women under the age of 25 and for individuals in high-risk groups.

Geographical Analysis

North America is expected to hold a significant position in the sexually transmitted diseases (STD) diagnostics market share

North America, especially the United States, has one of the highest rates of sexually transmitted diseases globally. The Centers for Disease Control and Prevention (CDC) reports that more than 2.5 million cases of chlamydia, gonorrhea, and syphilis were diagnosed in the United States between 2020 to 2021. The high incidence of STDs in this region drives the demand for diagnostic tests.

The U.S. has also seen significant challenges with HIV, a key part of the STD landscape. According to HIV.gov, more than 1.2 million Americans are currently living with HIV and many more are at risk of HIV infection. According to the CDC, around 38,000 people in the U.S. are diagnosed with HIV annually, contributing to the demand for regular HIV testing and diagnostics.

North America benefits from strong public health policies that promote regular STD testing, early diagnosis, and treatment. The CDC and other organizations run numerous programs aimed at increasing awareness and access to STD diagnostics. For instance, the "Get Yourself Tested" (GYT) campaign, which encourages young people to get tested for STDs, has significantly increased awareness and testing uptake, particularly among sexually active youth. This initiative has led to a greater demand for diagnostic services and kits.

North America leads in the adoption of advanced diagnostic technologies for STDs. Technologies such as at-home diagnostic kits, rapid diagnostic tests and point-of-care tests are widely used across the region due to their accuracy, ease of use, and quick results.

For instance, in August 2023, the iHealth Labs, Inc. (iHealth) Home Collection Kit for HIV and syphilis testing was released. In the privacy of their own home, anybody over the age of 18 can get a blood sample for testing for syphilis and HIV (I, II, and P24 antigen) using the FDA-approved solution. They can mail the sample to the lab with a pre-paid overnight label and receive accurate and private results in as little as two days. As the STD issue in the United States grew, iHealth responded by launching the first home collection solution in the STD OTC test category.

Asia-Pacific is growing at the fastest pace in the sexually transmitted diseases (STD) diagnostics market

The Asia-Pacific region, home to more than 4.5 billion people, has seen an alarming rise in the incidence of sexually transmitted diseases. According to the World Health Organization (WHO), Asia accounts for a significant percentage of global STD cases. In China, India, and Thailand, the incidence of STDs like chlamydia, gonorrhea, and syphilis is increasing, especially among young people and high-risk groups.

For instance, according to the National Institute of Health (NIH), globally, there are 376 million new cases of four curable STDs (chlamydia, gonorrhea, syphilis, and trichomoniasis) each year, with a significant portion occurring in Asia. In India, syphilis and chlamydia are among the most common STDs, leading to an increased need for diagnostic tests.

Over the past decade, there has been a growing awareness of sexual health issues, including the importance of STD testing, in many parts of Asia. This is primarily driven by global health campaigns, educational initiatives, and increased media coverage of STDs and HIV/AIDS prevention. For instance, In India, public health campaigns, such as those run by the India HIV/AIDS Alliance and Population Foundation of India, have been instrumental in spreading awareness about STDs and HIV, encouraging people to get tested, leading to more frequent testing and demand for diagnostic services.

Additionally, several governments in the Asia-Pacific region have recognized the importance of combating STDs and are investing in prevention, education, and diagnostic services. The Indian government, for instance, has launched the National AIDS Control Programme (NACP), which offers free testing and treatment for HIV, syphilis, and other STDs in many public health centers.

Competitive Landscape

The major global players in the sexually transmitted diseases (STD) diagnostics market include Abbott Laboratories, Becton, Dickinson, and Company, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Hologic, Inc., QIAGEN N.V., Diasorin S.p.A., Seegene Inc., Bosch Healthcare Solutions GmbH and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global sexually transmitted diseases (STD) diagnostics market report delivers a detailed analysis with 70 key tables, more than 70 visually impactful figures, and 188 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Disease Type
  • 2.5. Snippet by Diagnostic Test Type
  • 2.6. Snippet by End-User
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in STD Self-Diagnostics
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Awareness and Education
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Sexually Transmitted Diseases (STD) Diagnostics Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Instruments*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Consumables
  • 5.4. Software

6. Sexually Transmitted Diseases (STD) Diagnostics Market, By Disease Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 6.1.2. Market Attractiveness Index, By Disease Type
  • 6.2. Chlamydia*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Genital Herpes
  • 6.4. Gonorrhea
  • 6.5. Hepatitis B
  • 6.6. HIV/AIDS
  • 6.7. Human papillomavirus (HPV)
  • 6.8. Syphilis
  • 6.9. Others

7. Sexually Transmitted Diseases (STD) Diagnostics Market, By Diagnostic Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 7.1.2. Market Attractiveness Index, By Diagnostic Test Type
  • 7.2. Molecular Tests*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Serologic Tests
  • 7.4. Point-of-Care (PoC) Tests
  • 7.5. Others

8. Sexually Transmitted Diseases (STD) Diagnostics Market, By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Specialty Clinics
  • 8.4. Diagnostic Laboratories
  • 8.5. Homecare Settings
  • 8.6. Others

9. Sexually Transmitted Diseases (STD) Diagnostics Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. Abbott Laboratories*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. Becton, Dickinson, and Company
  • 11.3. F. Hoffmann-La Roche Ltd.
  • 11.4. Bio-Rad Laboratories, Inc.
  • 11.5. Thermo Fisher Scientific Inc.
  • 11.6. Hologic, Inc.
  • 11.7. QIAGEN N.V.
  • 11.8. Diasorin S.p.A.
  • 11.9. Seegene Inc.
  • 11.10. Bosch Healthcare Solutions GmbH

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us